Encrantz Staffan
SEC CIK 1870875 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| SGHT | Sight Sciences, Inc. | Dir, 10% | 1.43M | $34.66M | $2.06M | 22 | 2021-07-19 | 2026-06-10 |
Most active insiders at SGHT, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Badawi Paul | Pres, CEO, Dir, 10% | — | $770.5K |
| 2 | HAYDEN JEREMY B. | CLO | — | $666.9K |
| 3 | Bauerlein Alison | COO | — | $508.0K |
| 4 | Badawi David | CTO, Dir | — | $194.2K |
| 5 | Encrantz Staffan | Dir, 10% | $184.8K | — |
| 6 | Rodberg James | CFO | — | $139.6K |
| 7 | Taylor Brenton | EVP, Ops, R, D | — | $134.4K |
| 8 | Mazzacco Catherine | Dir | — | — |
| 9 | Fountain Tamara | Dir | — | — |
| 10 | Rashid Kashif | CLO | — | — |
Transactions 22
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-11 16:43 | 2026-06-10 | SGHT | Sight Sciences, Inc. | Encrantz Staffan | Dir, 10% | P - Purchase | $4.88 | +14.1K | 1.43M | +1.0% | +$68.8K | |
| 2026-06-05 16:10 | 2026-06-04 | SGHT | Sight Sciences, Inc. | Encrantz Staffan | Dir, 10% | A - Grant | $0.00 | +28.3K | 1.42M | +2% | $0 | |
| 2025-12-18 | 2025-12-16 | SGHT | Sight Sciences, Inc. | Encrantz Staffan | Dir, 10% | P - Purchase | $8.31 | +14.0K | 1.39M | +1% | +$116.0K | |
| M | 2025-06-06 | 2025-06-04+ | SGHT | Sight Sciences, Inc. | Encrantz Staffan | Dir, 10% | P - Purchase | $4.22 | +90.5K | 1.32M | +7% | +$381.8K |
| 2025-06-06 | 2025-06-05 | SGHT | Sight Sciences, Inc. | Encrantz Staffan | Dir, 10% | A - Grant | $0.00 | +31.0K | 1.35M | +2% | $0 | |
| M | 2025-06-03 | 2025-05-30+ | SGHT | Sight Sciences, Inc. | Encrantz Staffan | Dir, 10% | P - Purchase | $3.81 | +98.8K | 1.23M | +9% | +$376.6K |
| M | 2025-05-29 | 2025-05-27+ | SGHT | Sight Sciences, Inc. | Encrantz Staffan | Dir, 10% | P - Purchase | $3.53 | +128.2K | 1.16M | +12% | +$452.1K |
| MI | 2025-03-13 | 2025-03-10+ | SGHT | Sight Sciences, Inc. | Encrantz Staffan | Dir, 10% | J - Other | $2.70 | +513.0K | 5.09M | +11% | +$1.38M |
| I | 2024-11-21 | 2024-11-21 | SGHT | Sight Sciences, Inc. | Encrantz Staffan | Dir, 10% | S - Sale | $3.73 | -551.8K | 632.5K | -47% | -$2.06M |
| I | 2024-11-21 | 2024-11-21 | SGHT | Sight Sciences, Inc. | Encrantz Staffan | Dir, 10% | P - Purchase | $3.73 | +551.8K | 4.57M | +14% | +$2.06M |
| 2024-06-10 | 2024-06-06 | SGHT | Sight Sciences, Inc. | Encrantz Staffan | Dir | A - Grant | $0.00 | +17.4K | 1.03M | +2% | $0 | |
| M | 2023-12-01 | 2023-11-29+ | SGHT | Sight Sciences, Inc. | Encrantz Staffan | Dir, 10% | P - Purchase | $3.46 | +144.0K | 1.01M | +17% | +$498.4K |
| M | 2023-11-28 | 2023-11-24+ | SGHT | Sight Sciences, Inc. | Encrantz Staffan | Dir, 10% | P - Purchase | $3.37 | +521.9K | 614.5K | +563% | +$1.76M |
| M | 2023-11-22 | 2023-11-20+ | SGHT | Sight Sciences, Inc. | Encrantz Staffan | Dir, 10% | P - Purchase | $2.39 | +188.8K | 346.3K | +120% | +$450.8K |
| M | 2023-11-20 | 2023-11-16+ | SGHT | Sight Sciences, Inc. | Encrantz Staffan | Dir, 10% | P - Purchase | $2.19 | +127.0K | 30.8K | New | +$278.1K |
| 2023-11-16 | 2023-11-14 | SGHT | Sight Sciences, Inc. | Encrantz Staffan | Dir, 10% | P - Purchase | $2.00 | +3,462 | 30.5K | +13% | +$6,924 | |
| MA | 2023-11-16 | 2023-06-08 | SGHT | Sight Sciences, Inc. | Encrantz Staffan | Dir, 10% | A - Grant | $0.00 | +27.0K | 27.0K | New | $0 |
| M | 2023-06-12 | 2023-06-08 | SGHT | Sight Sciences, Inc. | Encrantz Staffan | Dir, 10% | A - Grant | $0.00 | +27.0K | 11.9K | New | $0 |
| MI | 2022-05-17 | 2022-05-13+ | SGHT | Sight Sciences, Inc. | Encrantz Staffan | Dir, 10% | P - Purchase | $8.33 | +551.8K | 551.8K | New | +$4.60M |
| MI | 2021-12-01 | 2021-11-29+ | SGHT | Sight Sciences, Inc. | Encrantz Staffan | Dir | P - Purchase | $20.89 | +525.0K | 3.58M | +17% | +$10.97M |
| I | 2021-10-20 | 2021-10-18 | SGHT | Sight Sciences, Inc. | Encrantz Staffan | Dir | P - Purchase | $24.00 | +527.0K | 3.50M | +18% | +$12.65M |
| DMI | 2021-07-19 | 2021-07-19 | SGHT | Sight Sciences, Inc. | Encrantz Staffan | Dir | C - Cnv Deriv | $0.00 | +3.60M | 632.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations